AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Novel Coronavirus Treatment

1,050.043

+2.5480.24%

Number of Gainers:8

Number of Losers:12

Number of Flat:12

PE:- -

High:1,050.497

Open:1,047.780

Low:1,040.184

Close:1,047.495

Loading ...

BRIEF-CSL Vifor And Travere Therapeutics Announce Standard EU Approval For Filspari® In Iga Nephropathy

CSL Vifor and Travere Therapeutics Announce Standard EU Approval for Filspari® in Iga Nephropathy

THOMSON REUTERS

ResMed's U.S. Manufacturing Likely to Boost Margins -- Market Talk

BRIEF-Dimerix Seeks Trading Halt

IDT Australia Ltd - No Impact on IDT Demand From Global Tariffs

THOMSON REUTERS

IDT Australia Ltd - Quarterly Revenue Jumps 30% to a$4.1 Million

THOMSON REUTERS

Mesoblast Appoints Corporate Finance Leader Lyn Cobley to Board

THOMSON REUTERS

Press Release: Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

BRIEF-Nanoveu Seeks Trading Halt

Dimerix - Seeks Trading Halt Pending Announcement on Licensing Agreement

THOMSON REUTERS

3 ASX 200 stocks to buy and hold forever without thinking twice

How Trump's tariffs have created 'upside potential' for CSL shares

ResMed's Tariff Exemption Bolsters Competitive Position -- Market Talk

ResMed's Tariff Exemption Should Support Multiples -- Market Talk

Healius Amends CEO's Terms of Employment

MT Newswires Live

Why buy and hold investing with ASX shares could be your smartest move yet

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK7501/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7501","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7501\",,,,,undefined,":{"symbol":"BK7501","market":"AU","secType":"PLATE","nameCN":"Novel Coronavirus Treatment","latestPrice":1050.0426,"timestamp":1746770399940,"preClose":1047.4948,"halted":0,"volume":36575034,"delay":0,"changeRate":0.002432,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":2.547852,"latestTime":"05-09 16:00:00 AEST","open":1047.7803,"high":1050.4968,"low":1040.1836,"amount":326949188,"amplitude":0.009846,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1747008000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1746748800000,1746770400000]],"turnoverRate":0.002586,"increases":8,"decrements":13,"flats":12,"marketCap":270774796759.5,"floatMarketCap":218808271575.96094},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7501\",,,,,undefined,":{"symbol":"BK7501","high":1050.4968,"amplitude":0.009846,"preClose":1047.4948,"low":1040.1836,"latestPrice":1050.0426,"volume":36575034,"delay":0,"open":1047.7803,"prevYearClose":1117.913,"prevWeekClose":1050.043,"prevMonthClose":1052.524,"prevQuarterClose":1021.93,"fiveDayClose":1079.952,"twentyDayClose":1037.854,"sixtyDayClose":1051.531,"secType":"PLATE","market":"AU","turnoverRate":0.002586,"marketCap":270774796759.5,"floatMarketCap":218808271575.96094,"timestamp":1746770399940,"nameCN":"Novel Coronavirus Treatment"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7501\",,,,undefined,":{"bkCode":"BK7501","up":8,"down":12,"flat":12},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7501\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531225933","title":"BRIEF-CSL Vifor And Travere Therapeutics Announce Standard EU Approval For Filspari® In Iga Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2531225933","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531225933?lang=en_us&edition=fundamental","pubTime":"2025-04-29 14:04","pubTimestamp":1745906694,"startTime":"0","endTime":"0","summary":"BRIEF-CSL Vifor And Travere Therapeutics Announce Standard EU Approval For Filspari In Iga NephropathyApril 29 (Reuters) - CSL Ltd CSL.AX:CSL VIFOR AND TRAVERE THERAPEUTICS ANNOUNCE STANDARD EU APPROV","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R62E1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVTX","CSL.AU","BK7067","BK7501","BK7508","BK7511"],"gpt_icon":0},{"id":"2531225879","title":"CSL Vifor and Travere Therapeutics Announce Standard EU Approval for Filspari® in Iga Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2531225879","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531225879?lang=en_us&edition=fundamental","pubTime":"2025-04-29 14:01","pubTimestamp":1745906478,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R62E1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7511","BK7067","BK7501","CSL.AU","TVTX","BK7508","BK4139"],"gpt_icon":0},{"id":"2531243161","title":"ResMed's U.S. Manufacturing Likely to Boost Margins -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2531243161","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531243161?lang=en_us&edition=fundamental","pubTime":"2025-04-29 11:36","pubTimestamp":1745897760,"startTime":"0","endTime":"0","summary":"0336 GMT - ResMed's expanded U.S. manufacturing footprint is seen by Goldman Sachs analysts as likely to further assist strong gross margin accretion at the breath-tech manufacturer. A 70bp expansion in 3Q gross margin was key to ResMed's stronger-than-expected profit for the period, they say. Keeping a buy rating on the stock, the analysts tell clients in a note that margin accretion to date reflects operating leverage from manufacturing capacity expansion, discipline on labor costs, and the optimization of raw materials. GS lifts its target price by 5.1% to A$49.30. Shares are down 0.7% at A$36.68. ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4516","LU2237443465.HKD","IE0004086264.USD","BK4588","LU1868836591.USD","LU1868836914.USD","LU1868836757.USD","BK4504","LU1868837136.USD","BK4567","LU2237443549.SGD","LU2237443978.SGD","BK4082","LU2177674079.SGD","LU2237438978.USD","LU2750360997.AUD","LU2750360641.GBP","RMD.AU","IE00B19Z3581.USD","RMD","LU0251142724.SGD","LU2471134523.USD","LU2008162690.USD","LU0170899867.USD","BK4552","LU0048573561.USD","IE0002270589.USD","BK7007","IE00B19Z3B42.SGD","LU1668664300.SGD","BK4533","LU2237443622.USD","BK4127","LU0061475181.USD","LU2471134879.HKD","BK4548","LU0106831901.USD","IE00BFXG1179.USD","LU0742534661.SGD","LU1791807156.HKD","LU2471134952.CNY","LU1868837300.USD","IE0034235188.USD","LU0251131958.USD","BK4550","LU2237443895.HKD","LU0096364046.USD","IE0004091025.USD","BK4585","BK7501"],"gpt_icon":0},{"id":"2531319216","title":"BRIEF-Dimerix Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2531319216","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531319216?lang=en_us&edition=fundamental","pubTime":"2025-04-29 09:44","pubTimestamp":1745891050,"startTime":"0","endTime":"0","summary":"BRIEF-Dimerix Seeks Trading HaltApril 29 (Reuters) - Dimerix Ltd DXB.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENT ON LICENSING AGREEMENTFurther company coverage: DXB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R62K9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7067","BK7508","DXB.AU"],"gpt_icon":0},{"id":"2531914692","title":"IDT Australia Ltd - No Impact on IDT Demand From Global Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2531914692","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531914692?lang=en_us&edition=fundamental","pubTime":"2025-04-29 08:04","pubTimestamp":1745885092,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R62DK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","IDT.AU","BK7096"],"gpt_icon":0},{"id":"2531464291","title":"IDT Australia Ltd - Quarterly Revenue Jumps 30% to a$4.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2531464291","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531464291?lang=en_us&edition=fundamental","pubTime":"2025-04-29 08:04","pubTimestamp":1745885092,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R62DK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","IDT.AU","BK7096"],"gpt_icon":0},{"id":"2531429967","title":"Mesoblast Appoints Corporate Finance Leader Lyn Cobley to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2531429967","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531429967?lang=en_us&edition=fundamental","pubTime":"2025-04-29 07:44","pubTimestamp":1745883858,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nTUA6QPWHD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","MSB.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2531299972","title":"Press Release: Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2531299972","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531299972?lang=en_us&edition=fundamental","pubTime":"2025-04-29 07:44","pubTimestamp":1745883840,"startTime":"0","endTime":"0","summary":"NEW YORK, April 28, 2025  -- Mesoblast , global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Lyn Cobley to its Board of Directors. Ms. Cobley has been a global leader in the financial services industry with over 30 years' experience in senior positions at international and domestic banks. Ms. Cobley has served as CEO of Westpac Institutional Bank, Group Treasurer of Commonwealth Bank of Australia, and held senior roles at Barclays Capital and Citibank Limited.Commenting on her appointment Ms. Cobley said, \"Following the recent United States Food and Drug Administration  approval of Ryoncil , Mesoblast has become a wonderful success story for not only the Australian biotechnology industry but the global leader in the allogeneic cell therapy industry. The Company has many exciting milestones in the near-term including ramp-up of commercialization and additional indications for some highly prevalent diseases. I look forward to co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4150","MSB.AU","BK7501","BK7508","BK4006","BK7067","MESO","MSB","MSC","BK4232","BK4575","BK4139","R","BK4022"],"gpt_icon":0},{"id":"2531791296","title":"BRIEF-Nanoveu Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2531791296","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531791296?lang=en_us&edition=fundamental","pubTime":"2025-04-29 07:31","pubTimestamp":1745883062,"startTime":"0","endTime":"0","summary":"BRIEF-Nanoveu Seeks Trading HaltApril 29 (Reuters) - Nanoveu Ltd NVU.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENT ON CAPITAL RAISINGFurther company coverage: NVU.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nFWN3R62KH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","NVU.AU","BK7076"],"gpt_icon":0},{"id":"2531298476","title":"Dimerix - Seeks Trading Halt Pending Announcement on Licensing Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2531298476","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531298476?lang=en_us&edition=fundamental","pubTime":"2025-04-29 06:32","pubTimestamp":1745879522,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nFWN3R62K9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","BK7501","DXB.AU"],"gpt_icon":0},{"id":"2531296883","title":"3 ASX 200 stocks to buy and hold forever without thinking twice","url":"https://stock-news.laohu8.com/highlight/detail?id=2531296883","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531296883?lang=en_us&edition=fundamental","pubTime":"2025-04-29 05:52","pubTimestamp":1745877144,"startTime":"0","endTime":"0","summary":"When it comes to building lasting wealth, few strategies are as powerful — or as simple — as buy and hold investing. Instead of trying to time the market or jump in and out of ASX 200 stocks based on ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/29/3-asx-200-stocks-to-buy-and-hold-forever-without-thinking-twice/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU1868837300.USD","BK4127","IE00B19Z3581.USD","CSL.AU","IE00BSNM7G36.USD","LU0251142724.SGD","LU2471134879.HKD","BK7094","LU0096364046.USD","LU2750360997.AUD","LU2237443549.SGD","BK4516","BK4552","LU1668664300.SGD","LU1868836591.USD","LU2237438978.USD","PME.AU","LU0061475181.USD","IE00BFXG1179.USD","BK4550","LU2237443622.USD","IE00B19Z3B42.SGD","BK7501","BK7503","LU0048573561.USD","BK4585","BK7508","BK7067","LU0251131958.USD","LU1791807156.HKD","LU1868836757.USD","LU0742534661.SGD","WTC.AU","LU1868836914.USD","LU1868837136.USD","LU2237443465.HKD","LU2237443978.SGD","LU2471134523.USD","BK4588","IE0034235188.USD","BK4533","LU2471134952.CNY","IE0004086264.USD","IE0004091025.USD","LU2750360641.GBP","BK7511","IE0002270589.USD","LU0106831901.USD","BK4504","LU2471134796.USD"],"gpt_icon":0},{"id":"2531926812","title":"How Trump's tariffs have created 'upside potential' for CSL shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2531926812","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531926812?lang=en_us&edition=fundamental","pubTime":"2025-04-29 02:30","pubTimestamp":1745865000,"startTime":"0","endTime":"0","summary":"CSL Ltd (ASX: CSL) shares have gone backwards over the past year. Shares in the S&P/ASX 200 Index(ASX: XJO) biotech stock closed up 0.99% on Monday trading for $244.29. Despite that welcome boost, sha","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/29/how-trumps-tariffs-have-created-upside-potential-for-csl-shares/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU1169590202.USD","BK7511","BK7067","BK7501","BK4086","LU1169589451.USD","CSL.AU","SG9999004303.SGD","SGXZ23171101.USD","XJO.AU","LU0728928796.USD","CSL","BK7508"],"gpt_icon":0},{"id":"2530415685","title":"ResMed's Tariff Exemption Bolsters Competitive Position -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2530415685","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530415685?lang=en_us&edition=fundamental","pubTime":"2025-04-28 11:54","pubTimestamp":1745812440,"startTime":"0","endTime":"0","summary":"0354 GMT - ResMed's exemption from U.S. tariffs supports the breath-tech provider's already strong competitive position, according to Morgans analyst Derek Jellinek. He tells clients in a note that the exemption is important, but that he already liked ResMed for its expanding U.S. manufacturing footprint, the emergence of new technologies driving adoption, and favorable trends in wearables and weight-loss drugs. Jellinek observes that growth in ResMed's U.S. mask sales continues to outpace that of the broader industry, with rest-of-world sales growth poised to eventually catch up. Morgans keeps an add rating on the stock and raises its target price 1.1% to A$44.07. Shares are up 2.6% at A$37.005.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4504","BK4567","LU2008162690.USD","LU2177674079.SGD","BK7007","RMD","RMD.AU","BK4585","BK4548","BK7501","BK4588","LU0170899867.USD"],"gpt_icon":0},{"id":"2530952894","title":"ResMed's Tariff Exemption Should Support Multiples -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2530952894","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530952894?lang=en_us&edition=fundamental","pubTime":"2025-04-28 09:20","pubTimestamp":1745803200,"startTime":"0","endTime":"0","summary":"0120 GMT - ResMed's bull at Macquarie expects its U.S. tariff exemption to help reverse the stock's recent compression in valuation multiples. The investment bank's analysts don't think the breath-tech manufacturer will feel any material impact from U.S. tariffs, and reiterate their outperform rating on the stock. New products, margin expansion, cash flow and capital deployment should also help grow multiples back toward previous levels, they add. In a note to clients, the analysts point out that stronger-than-expected mask sales and softer-than-expected device sales meant that 3Q U.S. revenue was in line with expectations. Macquarie trims its target price 1.6% to A$48.00. Shares are up 2.8% at A$37.075. ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD","RMD.AU","BK4082","BK7007","BK4588","LU0170899867.USD","BK7501","LU2008162690.USD","BK4504","BK4548","BK4567","BK4585","LU2177674079.SGD"],"gpt_icon":0},{"id":"2530846160","title":"Healius Amends CEO's Terms of Employment","url":"https://stock-news.laohu8.com/highlight/detail?id=2530846160","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530846160?lang=en_us&edition=fundamental","pubTime":"2025-04-28 07:09","pubTimestamp":1745795371,"startTime":"0","endTime":"0","summary":"Healthcare company Healius  changed the terms of employment of Chief Executive Officer Paul Anderson, according to a Monday filing with the Australian bourse.The CEO's tenure will now move to \"permanent ongoing employment, subject to termination,\" from a fixed term ending June 30, 2026.Anderson's fixed annual remuneration will also be increased to AU$1.3 million from AU$1.1 million, effective Jan. 1.Further, the CEO's fiscal year 2027 bonus arrangements will include short- and long-term incentives to align with the remuneration structure for other key management personnel, pending performance measures, the filing said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","BK7124","HLS.AU","BK7509"],"gpt_icon":0},{"id":"2530117461","title":"Why buy and hold investing with ASX shares could be your smartest move yet","url":"https://stock-news.laohu8.com/highlight/detail?id=2530117461","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530117461?lang=en_us&edition=fundamental","pubTime":"2025-04-27 05:15","pubTimestamp":1745702100,"startTime":"0","endTime":"0","summary":"Not every company is worthy of a permanent spot in your portfolio. Investors may want to look for ASX shares with a strong competitive advantage. Does the company have something special that is hard for rivals to replicate?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/27/why-buy-and-hold-investing-with-asx-shares-could-be-your-smartest-move-yet/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7135","BK7040","BK7508","BK7067","BK7153","BK7501","CBA.AU","WES.AU","BK7511","CSL.AU","BK7082","COL.AU","BK7041"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":6,"totalSize":116,"code":"91000000","status":"200"}]}}